Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Stoke Therapeutics's share price for the quarter that ended in Mar. 2026 was €27.4. Stoke Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 62.24 Mil. Therefore, Stoke Therapeutics's market cap for the quarter that ended in Mar. 2026 was €1,705.38 Mil.
Stoke Therapeutics's quarterly market cap
increased
from Sep. 2025 (€1,146.50 Mil) to Dec. 2025 (€1,590.89 Mil) and
increased
from Dec. 2025 (€1,590.89 Mil) to Mar. 2026 (€1,705.38 Mil).
Stoke Therapeutics's annual market cap
increased
from Dec. 2023 (€220.41 Mil) to Dec. 2024 (€567.35 Mil) and
increased
from Dec. 2024 (€567.35 Mil) to Dec. 2025 (€1,590.89 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Stoke Therapeutics's Enterprise Value for Today is €1,506.35 Mil.
Stoke Therapeutics (FRA:0GT) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Stoke Therapeutics Market Cap Related Terms
Stoke Therapeutics Market Cap Historical Data
* Premium members only.
The historical data trend for Stoke Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:0GT vs VRDN, ZLAB, NUVB: Market Cap Comparison
For the Biotechnology subindustry, Stoke Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stoke Therapeutics Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Stoke Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Stoke Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Stoke Therapeutics's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Stoke Therapeutics (FRA:0GT) has a Market Cap of €1,805.88 Mil as of Jul. 08, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Stoke Therapeutics and its competitors. According to the industry distribution chart, Stoke Therapeutics ranks #172 out of 1420 companies in the Biotechnology industry, placing it in the top 12.1%.
Is Stoke Therapeutics' Market Cap too high?
Stoke Therapeutics' current Market Cap is €1,805.88 Mil. Based on the distribution chart, Stoke Therapeutics ranks #172 out of 1420 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Stoke Therapeutics has a GF Score™ of 43/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Stoke Therapeutics' Market Cap compare to VRDN and ZLAB?
According to the Biotechnology industry distribution chart, Stoke Therapeutics ranks #172 out of 1420 companies for Market Cap. This places Stoke Therapeutics in the top 12% of its industry — outperforming the majority of peers. The industry median Market Cap is 121.52. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 121.52, based on 1,420 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Stoke Therapeutics and its competitors. For the Biotechnology industry, the median Market Cap is 121.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Stoke Therapeutics's current Market Cap is €1,805.88 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stoke Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Stoke Therapeutics (FRA:0GT) is currently considered Significantly Overvalued. The stock's GF Value™ is €8.56, compared to a current price of €27.72 — trading 223.8% above its estimated fair value. The current Market Cap is €1,805.88 Mil. Stoke Therapeutics' overall GF Score™ is 43/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Stoke Therapeutics (FRA:0GT), the current Market Cap is €1,805.88 Mil as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Stoke Therapeutics (FRA:0GT) Overvalued in 2026?
Based on GuruFocus' analysis, Stoke Therapeutics stock appears to be overvalued.
The current stock price of €27.72 is trading 223.8% above its estimated GF Value™ of €8.56.
GuruFocus considers Stoke Therapeutics to be Significantly Overvalued.
Key valuation signals for FRA:0GT:
Market Cap: €1,805.88 Mil
GF Value™: €8.56 vs. price of €27.72 (223.8% above fair value)
No single metric tells the full story. See the FRA:0GT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
43GF Score
Get the complete analysis for FRA:0GT
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:0GT has been successfully added to your 
